Mort Minaee has joined 454 Life Sciences as head of regulatory affairs. He will be responsible for the regulatory approval process as the company prepares for the diagnostic use of the 454 sequencing technology.
Minaee comes to 454 from Abbott Molecular Diagnostics, where he was director of regulatory and clinical affairs. At Abbott, he worked with Roche and Genentech on a companion diagnostic for the cancer drug Tarceva. In the past, he held a position with Siemens Medical Solutions, where he obtained approvals for software-based diagnostic devices.
Illumina CEO Jay Flatley has joined the board of directors Helixis, a Carlsbad, Calif.-based developer of nucleic acid analysis tools. Prior to coming to Illumina, Flatley was president and CEO of Molecular Dynamics, now part of GE Healthcare, and led that company's initial public offering in 1993.
Mari Baker has left her post as CEO of Navigenics to take the chief executive position at video game company PlayFirst. She will have "ongoing board roles" at Navigenics and Cozi Group, according to PlayFirst.